Lymphangioleiomyomatosis

Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002.

Abstract

Lymphangioleiomyomatosis is a rare multisystem disease predominantly affecting women that can occur sporadically or in association with tuberous sclerosis. Lung cysts progressively replace the lung parenchyma, which leads to dyspnea, recurrent pneumothorax, and in some cases respiratory failure. Patients may also have lymphatic disease in the thorax, abdomen, and pelvis, and renal angiomyolipomas. Treatment includes supportive care, bronchodilators, and for those with progressive disease, mammalian target of rapamycin (mTOR) inhibitors.

Keywords: Angiomyolipoma; Cystic lung disease; Lymphatic disease; Pneumothorax; mTOR inhibitor.

Publication types

  • Review

MeSH terms

  • Angiomyolipoma / complications
  • Angiomyolipoma / diagnostic imaging*
  • Angiomyolipoma / pathology
  • Angiomyolipoma / therapy
  • Antibiotics, Antineoplastic / therapeutic use
  • Bronchodilator Agents / therapeutic use
  • Everolimus / therapeutic use
  • Humans
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy
  • Lung Neoplasms / complications
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Lymphangioleiomyomatosis / complications
  • Lymphangioleiomyomatosis / diagnostic imaging*
  • Lymphangioleiomyomatosis / pathology
  • Lymphangioleiomyomatosis / therapy
  • Pleurodesis
  • Pneumothorax / etiology
  • Pneumothorax / therapy
  • Sirolimus / therapeutic use
  • Tomography, X-Ray Computed
  • Tuberous Sclerosis / complications
  • Tuberous Sclerosis / diagnostic imaging*
  • Tuberous Sclerosis / pathology
  • Ultrasonography

Substances

  • Antibiotics, Antineoplastic
  • Bronchodilator Agents
  • Everolimus
  • Sirolimus